Padma 28

About Padma 28

Padma 28 is the most-studied Tibetan-derived phytopharmaceutical registered in Europe. It is a twenty-herb compound plus natural camphor and calcium sulfate, manufactured by Padma AG in Schwerzenbach, Switzerland, and registered with Swissmedic as a phytotherapeutic for peripheral arterial occlusive disease (PAOD). The product descends from the Gabur-25 (Camphor-25) family of Tibetan formulas and was adapted during the twentieth century into a Swiss-pharmacy-compliant preparation.

The Padma 28 formulation traces to the Gabur-25 (Gabur-nyer-lnga) camphor-formula tradition carried out of Buryatia at the end of the nineteenth century by the court physician Dr. Pyotr (Peter) Badmaev, who adapted a Buryat-Mongolian reading of the Tibetan formulary for St. Petersburg practice. Vladimir Badmajew (Peter's nephew) carried the practice to Poland after the 1917 Revolution and ran a Tibetan pharmacy in Warsaw. His son, Peter Badmaev Jr., emigrated to Switzerland in 1965, and the family's recipe was developed there into a Swiss-registered medicine through Karl Lutz's Study Group for Tibetan Medicine (founded 1958). Padma AG, founded in 1969, has manufactured Padma 28 continuously since its Swiss registration in 1977 (Swissmedic No 35872).

Several ingredients in the classical Gabur-25 compound — including certain processed minerals — could not be registered under 1970s Swiss pharmaceutical regulation. Padma's reformulation substituted plant analogues and pharmacologically defensible minerals (natural camphor, calcium sulfate) for the unregisterable items while preserving the therapeutic intent of the parent formula. The "28" in the product name refers to the numbered position of the recipe in the Badmaev family's collection of Tibetan–Buryat formulas (it was the 28th entry), not to the ingredient count of either the classical or the Swiss preparation.

Padma 28 is one of the few Tibetan-derived compounds with a body of randomized controlled trial data in Western journals. Drabaek and colleagues (1993, Angiology) reported improved pain-free and maximum walking distance in stable intermittent claudication versus placebo. Melzer and colleagues (2006, Atherosclerosis) published a systematic review and meta-analysis of randomized trials in PAOD, concluding that Padma 28 produced clinically meaningful increases in pain-free walking distance compared with placebo. The Swissmedic registration for PAOD remains active.

In Swiss and German integrative cardiology practice, Padma 28 is prescribed alongside standard PAOD management (exercise therapy, antiplatelet agents, lipid control). It is not a replacement for revascularization in critical limb ischemia. In the living Tibetan tradition, the parent Gabur-25 camphor formula continues to be prepared in the classical way for heart-and-vessel indications, without the regulatory substitutions required for the Swiss preparation.

Ingredients

Twenty plant drugs plus natural camphor and calcium sulfate, per Padma AG's current PADMA 28N composition:

The exact compositional ratios are Padma AG proprietary. Aconite tuber (Aconitum napellus), historically present in small amounts in the original European Padma 28, is the single ingredient omitted in the US "Padma Basic" version; current PADMA 28N composition should be verified against Padma AG's published ingredient statement. Coral and other unregisterable mineral items present in the Tibetan parent formula are not in the Swiss preparation.

Preparation

Manufactured to GMP pharmaceutical standard in Switzerland. Each batch is released on the basis of standardized extract profiles and microbial-limits testing. The preparation is a film-coated tablet, not a traditional Tibetan ril-bu, and is not hand-rolled or ritually consecrated. This is a deliberate pharmaceutical departure from the classical preparation, in exchange for batch-to-batch standardization and European regulatory access.

Indications

Swissmedic-registered indication:

Investigational uses (not part of the Swiss registration):

Contraindications

Contraindicated in known hypersensitivity to any constituent, including plants of the Apiaceae family, and in acute inflammatory gastrointestinal disease. Not recommended in pregnancy and lactation due to insufficient safety data. Caution with concurrent anticoagulant and antiplatelet therapy — effects on platelet function have been reported. Not a substitute for revascularization in critical limb ischemia or acute arterial occlusion.

Dosage

Registered Swiss dosage: 2 tablets three times daily with water, before meals. Swiss product information recommends evaluating response after approximately 16 weeks; effect on walking distance typically emerges at 6–12 weeks.

Significance

Padma 28 occupies a singular place in the history of Sowa Rigpa: it is the only Tibetan-derived compound to have cleared a major Western regulatory pathway and accumulated a body of placebo-controlled trial evidence. For the integrative medicine field it is an exemplar of how a classical formula can be adapted to pharmaceutical standards while preserving therapeutic intent. For Tibetan practitioners it raises a live question about what gets preserved and what is lost when a consecrated compound is refactored for a regulatory regime that cannot accommodate coral, bezoar, or certain processed minerals.

Ayurvedic Parallel

Chebulic myrobalan (Terminalia chebula, haritaki) is the single overlap with Ayurvedic rasayana tradition; several aromatic drugs (cardamom, clove, costus) appear in Ayurvedic digestive and circulatory compounds, but no single Ayurvedic preparation maps closely to Padma 28.

TCM Parallel

Thematically parallels TCM blood-activating, stasis-resolving (huó xuè huà yū) formulas such as Xue Fu Zhu Yu Tang, though the pharmacology and botanical bases are distinct.

Connections

In its Tibetan parent form, see Gabur-25 (Gabur-nyer-lnga). Used alongside standard PAOD management and, in some European integrative clinics, with cardiovascular precious pills under specialist supervision.

Further Reading